 |
|
 |
 |
|
||||||||||||||
|
FDA panel to review diet drug Acomplia in June March 26, 2007 FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review the pros and cons of diet drug Rimonabant (Acomplia/Zimulti) on June 13, which will decide the fate of the eagerly awaited drug whether it will be approved for sale in the US or not. It was announced by Sanofi-Aventis, the firm developing the drug. However, it is likely that the FDA committee will be concentrating on the safety issues of the diet drug Acomplia as already many studies have shown that the drug in its first year of use helps significantly in loosing weight. It also improves other cardio metabolic risk factors such as cholesterol. According to a statement released by Sanofi-Aventis, it said it is pleased to have the opportunity to present its data on Rimonabant and to exchange with experts. Diet drug Acomplia is the first in a class of drugs that operates by blocking CB-1 receptors in the brain, and has been linked to depression and other psychotic side effects. If the drug is given signal for sale in the US then it will be marketed there as "Zimulti" though the drug is already on sale in European countries as well as Mexico and Argentina as Rimonabant. Medicine |
||||||||||||||
